Europeanhhm
BD - Earth day 2024

Terumo BCT secures first of its kind approval for Reveos® Automated Whole Blood Processing System

Terumo Blood and Cell Technologies (Terumo BCT) has announced the approval of the Reveos Automated Whole Blood Processing System by the U.S. Food and Drug Administration (FDA). This groundbreaking system is the first of its kind in the United States and facilitates the automated processing of whole blood into platelets and other essential components in a single centrifugation cycle. The introduction of the Reveos system is expected to substantially improve the availability of platelets and other blood components for patients across the country, benefiting those dealing with conditions such as trauma and cancer.

The Reveos system simplifies and automates the intricate process of separating whole blood into its various components, which include platelets, plasma, and red blood cells. This revolutionary automation is anticipated to reduce the workload of laboratory staff by up to 30%, enhance operational efficiency, and minimize costs.

The system's successful track record in over 52 countries over the past decade demonstrates its ability to support blood centers worldwide in meeting patient requirements while streamlining their operations. Additionally, the clearance of Reveos includes the IMUGARD WB Platelet Pooling Set, allowing for increased flexibility in platelet pooling for blood centers using the system.

Reveos streamlines the traditional process of whole blood processing by integrating manual steps, significantly reducing complexity, and maximizing the yield of blood products from a single donor. By doing so, it is poised to play a critical role in helping U.S. blood centers address the growing demand for platelets, which are vital for managing bleeding and treating various medical conditions.

The operational procedure of Reveos involves loading up to four units of whole blood into the system, initiating centrifugation, and subsequently collecting separated components such as platelets, plasma, red blood cells, and residual leukocytes in designated product bags.

In conclusion, the Reveos Automated Whole Blood Processing System by Terumo BCT marks a groundbreaking advancement in blood processing technology. It is set to revolutionize the availability of blood components, especially platelets, through automation, efficiency, and increased yield, thereby significantly benefiting patients in need.

https://www.prnewswire.com/news-releases/terumo-blood-and-cell-technologies-reveos-automated-whole-blood-processing-system-cleared-by-fda-for-us-commercial-use-301889788.html 


 

The Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO Summit